Message from the editors to our reviewers

Robert A. Gross; Bradford B. Worrall; Anthony A. Amato; Gregory D. Cascino; Olga Ciccarelli; John R. Corboy; Josep O. Dalmau; Rebecca F. Gottesman; Murray Grossman; John J. Millichap; Jonathan W. Mink; Stefan M. Pulst; Ryan J. Uitti

doi:10.1212/WNL.0000000000004780

Message from the editors to our reviewers

Robert A. Gross, Bradford B. Worrall, Anthony A. Amato, Gregory D. Cascino, Olga Ciccarelli, John R. Corboy, Josep O. Dalmau, Rebecca F. Gottesman, Murray Grossman, John J. Millichap, Jonathan W. Mink, Stefan M. Pulst, Ryan J. Uitti

School of Medicine

Research output: Contribution to journal › Editorial › peer-review

Original language	English (US)
Pages (from-to)	3-11
Number of pages	9
Journal	Neurology
Volume	90
Issue number	1
DOIs	https://doi.org/10.1212/WNL.0000000000004780
State	Published - Jan 2018

ASJC Scopus subject areas

Clinical Neurology

Access to Document

10.1212/WNL.0000000000004780

Cite this

@article{8458eaf4636c49508b5200da218f6da0,

title = "Message from the editors to our reviewers",

author = "Gross, {Robert A.} and Worrall, {Bradford B.} and Amato, {Anthony A.} and Cascino, {Gregory D.} and Olga Ciccarelli and Corboy, {John R.} and Dalmau, {Josep O.} and Gottesman, {Rebecca F.} and Murray Grossman and Millichap, {John J.} and Mink, {Jonathan W.} and Pulst, {Stefan M.} and Uitti, {Ryan J.}",

note = "Funding Information: Jonathan W. Mink, MD, PhD, FAAN, receives research support from NIH/NINDS, the Batten Research Alliance, CDC, and Abeona, Inc. He receives a consulting fee from Edison Pharmaceuticals for service on a Data and Safety Monitoring Board. He is a consultant for Medtronic, Inc., BioMarin, Inc., and Censa, Inc. He is an Editorial Board Member for Continuum, Pediatric Neurology, and the Journal of Child Neurology. Dr. Mink has received honoraria from the Tourette Association of America and receives an honorarium as Associate Editor of Neurology. Funding Information: Bradford B. Worrall, MD, MSc, FAAN, FANA, FAHA, has received research funding from NIH (multiple grants). He serves as an ad hoc reviewer for the NIH, Veterans Administration, and UK-MRC study sections. Dr. Worrall received several honoraria for serving as faculty and/or director for courses at the AAN annual meetings. Dr. Worrall receives an honorarium as Deputy Editor of Neurology. Funding Information: Olga Ciccarelli, MD, PhD, FRCP, receives research support from the UK MS Society, National MS Society, Rosetrees Trust, ECTRIMS/MAGNIMS, EU Horizon 2020, and National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (BRC). She serves as a consultant for Biogen, Novartis, Teva, Genzyme, and Roche. She is on the Editorial Board of Multiple Sclerosis Journal and receives an honorarium from the AAN as Associate Editor of Neurology. Funding Information: Ryan J. Uitti, MD, FAAN, has received research funding from the NIH, Noscira, Inc., Boston Scientific, and Abbott. His institution has received annual royalties from the licensing of the technology related to PARK8/LRRK2 greater than the federal threshold for significant financial interest. Dr. Uitti has not received any royalties. Dr. Uitti receives an honorarium as Associate Editor of Neurology. Funding Information: John J. Millichap, MD, FAAP, receives research support from NIH, Citizens United for Research in Epilepsy (CURE), Thrasher Research Fund, and UCB Pharma. He volunteers on the Medical Advisory Board of The Jack Pribaz Foundation (KCNQ2.org) and as the Editor of Pediatric Neurology Briefs. He receives royalties for online monographs from UpToDate and BMJ Best Practice. He served as a consultant for Mallink-rodt, UCB, Eisai, and BioMarin. He receives an honorarium as Associate Editor of Neurology. Funding Information: Robert A. Gross, MD, PhD, FAAN, is supported for educational endeavors by the University of Rochester Medical Center{\textquoteright}s Clinical and Translational Science Award from the NIH. Since his appointment as Editor-in-Chief in 2009, Dr. Gross has ceased participation in industry-sponsored clinical trials and speakers{\textquoteright} bureaus. He receives an honorarium from AAN as Editor-in-Chief of Neurology. Funding Information: Stefan-M. Pulst, MD, Dr med, FAAN, receives research support from the NIH and the National Ataxia Foundation. He is on the Editorial Boards of the Journal of Cerebellum, NeuroMolecular Medicine, Experimental Neurology, Neurogenetics, and Nature Clinical Practice Neurology. He receives book publishing royalties from Elsevier. He holds several patents for chemical compositions and methods of treatment. Dr. Pulst receives an honorarium as the Editor of Neurology{\textregistered} Genetics. Funding Information: Murray Grossman, MD, CM, FAAN, is supported by the NIH as principal investigator, core leader, or project leader; the Wyncote Foundation; the Arking Family Foundation; and the Samuel Newhouse Foundation. He is Chair of the Behavioral Neurology Section, AAN; and Chair, Society for Behavioral and Cognitive Neurology. He is on the Medical Advisory Board of the Association for Frontotemporal Degenerations and on the Executive Board of the International Society for Frontotemporal Dementia. Dr. Grossman is on the Editorial Board of Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. He receives research funding for imaging studies sponsored by Piramal and Avid. He participates in clinical trials sponsored by Biogen, Bristol Myers Squibb, Avid Radiopharmaceuticals, and TauRx Pharmaceuticals. He receives an honorarium as Associate Editor of Neurology. Funding Information: Josep O. Dalmau, MD, PhD, conducts research supported by NIH RO1NS077851 (previously RO1CA107192) (PI), Instituto Carlos III (FIS 14/00203 and PIE 16/00014), Ag{\`e}ncia de Gesti{\'o} d{\textquoteright}Ajuts Universitaris i de Recerca (AGAUR, Generalitat de Catalunya), Euroimmun, and CELLEX Foundation. He consults for Advance Medica and holds the following patents: Ma2 autoantibody test: patent number 6,387,639; NMDA receptor autoantibody test: US patent number 7,972,796 B2, European patent number 2057466; and GABA(B) receptor autoantibody test: US patent number 8,685,656. Patents are filed for GABA(A) receptor autoantibody test, DPPX autoantibody test, and IgLON5 autoantibody test. In 2016, Dr. Dalmau received a one-time licensing fee for the Iglon5 autoantibody test/Euroimmun. He is on the Editorial Boards of Neurology and UpToDate, and receives a stipend as the Editor of Neurology{\textregistered} Neuroimmunology & Neuroinflammation. Funding Information: John R. Corboy, MD, FAAN, conducts research supported by Novartis, the National Multiple Sclerosis Society, Patient-Centered Outcomes Research Institute, Biogen Idec, and Med Day. Dr. Corboy has received honoraria for speaking from Prime CME and the Rocky Mountain MS Center. He is an Associate Editor of Neurology and Editor of Neurology{\textregistered}: Clinical Practice.",

year = "2018",

month = jan,

doi = "10.1212/WNL.0000000000004780",

language = "English (US)",

volume = "90",

pages = "3--11",

journal = "Neurology",

issn = "0028-3878",

publisher = "Lippincott Williams and Wilkins",

number = "1",

}

TY - JOUR

T1 - Message from the editors to our reviewers

AU - Gross, Robert A.

AU - Worrall, Bradford B.

AU - Amato, Anthony A.

AU - Cascino, Gregory D.

AU - Ciccarelli, Olga

AU - Corboy, John R.

AU - Dalmau, Josep O.

AU - Gottesman, Rebecca F.

AU - Grossman, Murray

AU - Millichap, John J.

AU - Mink, Jonathan W.

AU - Pulst, Stefan M.

AU - Uitti, Ryan J.

N1 - Funding Information: Jonathan W. Mink, MD, PhD, FAAN, receives research support from NIH/NINDS, the Batten Research Alliance, CDC, and Abeona, Inc. He receives a consulting fee from Edison Pharmaceuticals for service on a Data and Safety Monitoring Board. He is a consultant for Medtronic, Inc., BioMarin, Inc., and Censa, Inc. He is an Editorial Board Member for Continuum, Pediatric Neurology, and the Journal of Child Neurology. Dr. Mink has received honoraria from the Tourette Association of America and receives an honorarium as Associate Editor of Neurology. Funding Information: Bradford B. Worrall, MD, MSc, FAAN, FANA, FAHA, has received research funding from NIH (multiple grants). He serves as an ad hoc reviewer for the NIH, Veterans Administration, and UK-MRC study sections. Dr. Worrall received several honoraria for serving as faculty and/or director for courses at the AAN annual meetings. Dr. Worrall receives an honorarium as Deputy Editor of Neurology. Funding Information: Olga Ciccarelli, MD, PhD, FRCP, receives research support from the UK MS Society, National MS Society, Rosetrees Trust, ECTRIMS/MAGNIMS, EU Horizon 2020, and National Institute for Health Research (NIHR) University College London Hospitals (UCLH) Biomedical Research Centre (BRC). She serves as a consultant for Biogen, Novartis, Teva, Genzyme, and Roche. She is on the Editorial Board of Multiple Sclerosis Journal and receives an honorarium from the AAN as Associate Editor of Neurology. Funding Information: Ryan J. Uitti, MD, FAAN, has received research funding from the NIH, Noscira, Inc., Boston Scientific, and Abbott. His institution has received annual royalties from the licensing of the technology related to PARK8/LRRK2 greater than the federal threshold for significant financial interest. Dr. Uitti has not received any royalties. Dr. Uitti receives an honorarium as Associate Editor of Neurology. Funding Information: John J. Millichap, MD, FAAP, receives research support from NIH, Citizens United for Research in Epilepsy (CURE), Thrasher Research Fund, and UCB Pharma. He volunteers on the Medical Advisory Board of The Jack Pribaz Foundation (KCNQ2.org) and as the Editor of Pediatric Neurology Briefs. He receives royalties for online monographs from UpToDate and BMJ Best Practice. He served as a consultant for Mallink-rodt, UCB, Eisai, and BioMarin. He receives an honorarium as Associate Editor of Neurology. Funding Information: Robert A. Gross, MD, PhD, FAAN, is supported for educational endeavors by the University of Rochester Medical Center’s Clinical and Translational Science Award from the NIH. Since his appointment as Editor-in-Chief in 2009, Dr. Gross has ceased participation in industry-sponsored clinical trials and speakers’ bureaus. He receives an honorarium from AAN as Editor-in-Chief of Neurology. Funding Information: Stefan-M. Pulst, MD, Dr med, FAAN, receives research support from the NIH and the National Ataxia Foundation. He is on the Editorial Boards of the Journal of Cerebellum, NeuroMolecular Medicine, Experimental Neurology, Neurogenetics, and Nature Clinical Practice Neurology. He receives book publishing royalties from Elsevier. He holds several patents for chemical compositions and methods of treatment. Dr. Pulst receives an honorarium as the Editor of Neurology® Genetics. Funding Information: Murray Grossman, MD, CM, FAAN, is supported by the NIH as principal investigator, core leader, or project leader; the Wyncote Foundation; the Arking Family Foundation; and the Samuel Newhouse Foundation. He is Chair of the Behavioral Neurology Section, AAN; and Chair, Society for Behavioral and Cognitive Neurology. He is on the Medical Advisory Board of the Association for Frontotemporal Degenerations and on the Executive Board of the International Society for Frontotemporal Dementia. Dr. Grossman is on the Editorial Board of Amyotrophic Lateral Sclerosis and Frontotemporal Degeneration. He receives research funding for imaging studies sponsored by Piramal and Avid. He participates in clinical trials sponsored by Biogen, Bristol Myers Squibb, Avid Radiopharmaceuticals, and TauRx Pharmaceuticals. He receives an honorarium as Associate Editor of Neurology. Funding Information: Josep O. Dalmau, MD, PhD, conducts research supported by NIH RO1NS077851 (previously RO1CA107192) (PI), Instituto Carlos III (FIS 14/00203 and PIE 16/00014), Agència de Gestió d’Ajuts Universitaris i de Recerca (AGAUR, Generalitat de Catalunya), Euroimmun, and CELLEX Foundation. He consults for Advance Medica and holds the following patents: Ma2 autoantibody test: patent number 6,387,639; NMDA receptor autoantibody test: US patent number 7,972,796 B2, European patent number 2057466; and GABA(B) receptor autoantibody test: US patent number 8,685,656. Patents are filed for GABA(A) receptor autoantibody test, DPPX autoantibody test, and IgLON5 autoantibody test. In 2016, Dr. Dalmau received a one-time licensing fee for the Iglon5 autoantibody test/Euroimmun. He is on the Editorial Boards of Neurology and UpToDate, and receives a stipend as the Editor of Neurology® Neuroimmunology & Neuroinflammation. Funding Information: John R. Corboy, MD, FAAN, conducts research supported by Novartis, the National Multiple Sclerosis Society, Patient-Centered Outcomes Research Institute, Biogen Idec, and Med Day. Dr. Corboy has received honoraria for speaking from Prime CME and the Rocky Mountain MS Center. He is an Associate Editor of Neurology and Editor of Neurology®: Clinical Practice.

PY - 2018/1

Y1 - 2018/1

UR - http://www.scopus.com/inward/record.url?scp=85069041492&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069041492&partnerID=8YFLogxK

U2 - 10.1212/WNL.0000000000004780

DO - 10.1212/WNL.0000000000004780

M3 - Editorial

AN - SCOPUS:85069041492

SN - 0028-3878

VL - 90

SP - 3

EP - 11

JO - Neurology

JF - Neurology

IS - 1

ER -

Message from the editors to our reviewers

ASJC Scopus subject areas

Access to Document

Other files and links

Cite this